AI-guided Solution for Selecting Ovarian Cancer Patients for Bevacizumab Monoclonal Therapy

Ovarian cancer treatment outcomes can vary significantly among patients, making personalized therapy selection crucial. This research aims to develop an AI-guided solution leveraging advanced multimodal artificial intelligence techniques to predict which ovarian cancer patients will benefit from Bevacizumab monoclonal therapy. The multimodal AI must provide accurate, rapid, and reliable predictions by analyzing diverse data sources—including histopathological whole slide images, clinical records, and genomic information. This solution is intended to enhance treatment effectiveness and help reduce unnecessary side effects and healthcare costs.